登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Her2 >HE2-H82E2

Biotinylated Human Her2 / ErbB2 Protein, His,Avitag™, premium grade

分子别名(Synonym)

ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1

表达区间及表达系统(Source)

Biotinylated Human Her2, His,Avitag, premium grade (HE2-H82E2) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).

Predicted N-terminus: Thr 23

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Request for sequence

蛋白结构(Molecular Characterization)

Her2 Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 72.9 kDa. The protein migrates as 101 kDa±3 kDa under reducing (R) condition, and 94 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Biotinylation)

As determined by Quantitative ELISA binding assay against streptavidin.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Her2 SDS-PAGE

Biotinylated Human Her2, His,Avitag, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

Her2 SEC-MALS

The purity of Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) is more than 90% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-FACS

Her2 FACS

2e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1 μg/mL of Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

Protocol

 

活性(Bioactivity)-ELISA

Her2 ELISA

Immobilized Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Pertuzumab Biosimilar with a linear range of 0.2-8 ng/mL (QC tested).

Protocol

Her2 ELISA

Immobilized Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Trastuzumab Biosimilar with a linear range of 0.2-2 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

Her2 SPR

Trastuzumab Biosimilar captured on Protein A Chip can bind Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 7.49 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

 
 
ACRO质量管理体系
 
 

背景(Background)

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

文献引用(Citations)

 

前沿进展

Electroconvulsive Therapy in Cochlear Implant Users
Crotty, Alshehri, Gendre et al
J ECT (2025)
Abstract: Cochlear implant manufacturers currently contraindicate the use of electroconvulsive therapy (ECT) in CI users, citing theoretical evidence of potential harm to the patient or the implant despite a lack of clinical data. We report two uncomplicated cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral CIs.The first case involves a 66-year-old visually impaired male with bilateral CIs. He suffered from major depressive disorder complicated by refusal of oral intake despite maximal pharmacological therapy. He underwent 9 consecutive cycles of bilateral ECT, after which his psychiatric condition improved. Cochlear implant function remained unchanged following the procedure. The second case involved a 65-year-old female with a left-sided CI and a history of recurrent depressive disorder. Her condition deteriorated with the onset of auditory hallucinations and increased suicidality. She underwent 8 consecutive cycles of unilateral ECT with right-sided electrode placement. Her psychiatric condition improved, and there was no change in CI impedance following the procedure.We report 2 successful cases of ECT in CI users, including the first reported case of bilateral ECT in a patient with bilateral cochlear implants. Further investigation into the safety of ECT in CI users is warranted to ensure that this crucial treatment modality remains available to this vulnerable patient cohort.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Design of Porous 3D Interdigitated Current Collectors and Hybrid Microcathodes for Zn-Ion Microcapacitors
Fan, Naresh, Zhu et al
ACS Nano (2025)
Abstract: Zinc-ion microcapacitors (ZIMCs) have gained considerable attention for their intrinsic charge storage mechanisms, combining a battery-type anode with a capacitor-type cathode. However, their development is constrained by challenges related to electrode material selection and microscale device design, especially given the limited footprint of such devices. Despite their potential, exploration of smart electrode processing and hybrid materials for on-chip ZIMCs remains limited. In this work, we introduce 3D gold interdigitated electrodes (3D Au IDEs) as highly porous current collectors, loaded with zinc (Zn) as the anode and hybrid activated carbon coated with PEDOT (AC-PEDOT) as the cathode, using an advanced microplotter fabrication technique. Compared with planar Zn//AC ZIMCs, where Zn and AC materials are loaded onto planar Au IDEs, the 3D Au Zn//AC-PEDOT ZIMCs demonstrate significantly enhanced performance. This is attributed to the critical role of IDEs in increasing the charge storage capacity, improving long-term cycling stability, and boosting capacitive-controlled charge storage contributions. The 3D Au Zn//AC-PEDOT ZIMCs achieve an areal capacity of 1.3 μAh/cm2, peak areal energy of 1.11 μWh/cm2, and peak areal power of 640 μW/cm2, surpassing most reported microsupercapacitors. This study highlights how optimized collectors and hybrid electrodes enhance microdevice charge storage while maximizing performance within a constrained footprint.
Protocol for evaluating neuronal activity and neurotransmitter release following amyloid-beta oligomer injections into the rat hippocampus
Hervé, Bonenfant, Amyot et al
STAR Protoc (2025) 6 (2), 103712
Abstract: In Alzheimer's disease, there is an imbalance in neurotransmitter release and altered neuronal activation. Here, we present a protocol approach to analyze neuronal activity by combining local field potential (LFP) recording with microdialysis within the same animal. We describe steps for measuring glutamate and GABA levels following hippocampal amyloid-beta oligomer (Aβo) injections in rats. We then detail procedures for assembling the electrode and cannula, surgical implantation and simultaneous in vivo LFP recording, interstitial fluid collection, and Aβo injections.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Can Difluoroethylene Carbonate Replace Fluoroethylene Carbonate for High-Performance Lithium-Ion Cells at High Voltage?
Guan, Ouyang, Wan et al
ACS Appl Mater Interfaces (2025)
Abstract: To date, optimizing electrolytes has become a promising approach to enable high-voltage, high-performance lithium-ion cells. Herein, a study is performed to evaluate the potential of difluoroethylene carbonate (DFEC) to replace fluoroethylene carbonate (FEC) and deliver comparable or even superior performance at high voltage. It is unveiled that moderately increasing lithium salt inside the DFEC-based electrolyte enhances the high-voltage performance of cells, with the DFEC-based electrolyte outperforming the FEC-based counterpart. Moreover, the DFEC-based electrolyte also fits the LiFePO4 system where a high performance is illustrated when charged to 3.8 and 4.0 V. As a result of the low binding energy between DFEC and Li+, an anion-rich solvation structure is formed by the DFEC-based electrolyte, facilitating Li+ intercalation/deintercalation and forming inorganic-rich passivation layers. In addition, the cell's electrode-electrolyte interface is well-protected due to the superior film property of DFEC, where a thin, smooth, and robust passivation layer is generated that efficiently prevents the electrode and electrolyte from side reactions under high voltage. Furthermore, the DFEC-based electrolyte and the cells containing it also demonstrate superior safety properties when exposed to typical safety testing. Hence, DFEC is shown to be a viable alternative to FEC for enabling sound-performance lithium-ion cells at a high voltage.
Showing 1-4 of 310892 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Her2靶点信息
英文全称:Receptor protein-tyrosine kinase erbB-2
中文全称:受体蛋白酪氨酸激酶 erbB-2
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:201详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定